The role of CT scanning in assessment of progression of men with CRPC

A newly published paper in the journal Cancer seems to be implying that every man with castration-resistant prostate cancer who progresses from non-metastatic to metastatic status (based on a bone scan or other indicators) should also be given a CT scan because of risk for soft tissue metastasis. … READ MORE … >

Is there ANY role for estramustine phosphate in treatment of CRPC today?

The appropriate, individual treatment of men with metastatic and non-metastatic forms of castration-resistant prostate cancer (CRPC) has become vastly more complicated over the past 5 years. … READ MORE …

Does cabazitaxel have targeted potential in late stage prostate cancer?

A research team working just down the street here in Philadelphia thinks cabazitaxel (Jevtana) may have expanded potential in treatment of some men with castration-resistant prostate cancer (CRPC). … READ MORE …

TARP trial shows limited benefits from 5-ARI + an anti-androgen in CRPC

For some 15+ years there have been subsets of patients and physicians who have believed strongly that adding a 5α-reductase inhibitor (5-ARI) like finasteride or dutasteride to an anti-androgen would quite certainly aid in the prevention of prostate cancer progression because such a regimen would reduce levels of dihydrotestosterone. … READ MORE …

Low-dose diethystilbestrol in treatment of men with CRPC

It has been a long time since we saw any truly new data on the efficacy and safety of a very old form of hormonal therapy (diethylstilbestrol or DES) in the treatment of advanced prostate cancer. … READ MORE …

Innocrin Pharmaceuticals moving VT-464 into Phase II portion of Phase I/II trial

Innocrin Pharmaceuticals has been conducting the Phase I portion of a Phase I /II trial of VT-464, a CYP17 lyase inhibitor, in men with treatment-naïve CRPC and in CRPC patients who have failed prior therapy with abiraterone, enzalutamide, and/or chemotherapy. … READ MORE …

Who’s actually dying of prostate cancer (in France) today?

A newly published paper from a French research group has provided some interesting data on which patients actually die of prostate cancer in the modern, post-PSA era. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,370 other followers